Meeting
2013 ASCO Annual Meeting
A randomized phase II study adding axitinib to pemetrexed-cisplatin in patients with malignant pleural mesothelioma (MPM): Clinical results of a single-center trial.
Authors
Wieneke A. Buikhuisen
Department of Thorax Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands
Wieneke A. Buikhuisen , Andrew D. Vincent , Marion M. Scharpfenecker , Catharina M. Korse , Arjan W. Griffioen , Renee van Pel , Paul Baas
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer - Non-small Cell Local-regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Mesothelioma
Clinical Trial Registration Number
NCT01211275
Citation
J Clin Oncol 31, 2013 (suppl; abstr 7528)
DOI
10.1200/jco.2013.31.15_suppl.7528
Abstract #
7528
Poster Bd #
22
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
ATOMIC-Meso: A randomized phase 2/3 trial of ADI-PEG20 or placebo with pemetrexed and cisplatin in patients with argininosuccinate synthetase 1-deficient non-epithelioid mesothelioma.
First Author: Peter Wojciech Szlosarek
Poster
2012 ASCO Annual Meeting
Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma (MPM).
First Author: Lee M. Krug
Poster
2021 ASCO Annual Meeting
DREAM3R: Durvalumab with chemotherapy as first-line treatment in advanced pleural mesothelioma—A phase 3 randomized trial.
First Author: Patrick M. Forde
Poster
2018 ASCO Annual Meeting
SWOG S0905: A randomized phase II study of cediranib versus placebo in combination with cisplatin and pemetrexed in chemonaive patients with malignant pleural mesothelioma.
First Author: Anne S. Tsao